Friday, July 10, 2026
🇺🇸 FDA

pharma · Colitis, Ulcerative · Multiple Myeloma

Janssen Cilag International

Janssen Cilag International NV

Janssen Cilag International clinical programs — 17 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
46
Drugs
37
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Janssen Cilag International projects

17 ClinicalTrials.gov programs sponsored by Janssen Cilag International.

Janssen Cilag International has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

17 programs

Clinical programs

  1. AL-335

    Janssen Cilag International NV

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  2. Apalutamide

    Janssen Cilag International NV

    Salivary Gland Neoplasms

    phase 2 small molecule active

    1 trial

  3. Azacitidine

    Janssen Cilag International NV

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  4. Cetrelimab

    Janssen Cilag International NV

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  5. Erdafitinib Intravesical Delivery System

    Janssen Cilag International NV

    Non-Muscle Invasive Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  6. Guselkumab

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 2 mab active

    1 trial

  7. JNJ-40411813

    Janssen Cilag International NV

    Focal Onset Seizures

    phase 2 small molecule completed

    1 trial

  8. JNJ-64281802

    Janssen Cilag International NV

    Dengue

    phase 2 small molecule terminated

    2 trials

  9. JNJ-73763989

    Janssen Cilag International NV

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  10. JNJ-77242113

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  11. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  12. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Viruses

    phase 2 small molecule terminated

    1 trial

  13. Placebo

    Janssen Cilag International NV

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  14. Rilematovir

    Janssen Cilag International NV

    Respiratory Syncytial Virus

    phase 2 small molecule terminated

    1 trial

  15. Rilpivirine

    Janssen Cilag International NV

    HIV-1

    phase 2 small molecule completed

    1 trial

  16. Siltuximab

    Janssen Cilag International NV

    Multicentric Castleman's Disease

    phase 2 small molecule completed

    1 trial

  17. TMC207

    Janssen Cilag International NV

    Tuberculosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Janssen Cilag International have?

17 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.